Towards the end of the last century the expression of 'personalised medicine' has come to life. This simply means the right drug for the right patient with the right dose. We all now understand that the difference between any individuals regarding their DNA sequence is only about 0.1%. In spite of the fact that this is really a tiny figure, it is enough to lead to important effects on disease susceptibility and progression. Although the healthcare community in Egypt and Lebanon has identified the need for academic educational programs on pharmacogenomics and personalised medicine, yet there has been no appreciable effort done in either country so far to fill this gap. Even the awareness of such programs is low. There exists no higher educational degree for pharmacogenomics in Egypt or Lebanon. Thus, there is a pressing need to implement this personalized medicine educational program in core training of pharmacists and physicians in the region. Moreover, there are very few programs in Egypt or Lebanon that make use of online education using IT and e-laboratories. This kind of smart learning programs facilitate the education process and make it suitable for the greatest numbers of target groups outside the Egyptian and Lebanese borders. Identification of the proper drugs for specific patient phenotypes will heighten the drug efficacy, lessen expected adverse outcomes, increase cost effectiveness and elevate public confidence in marketed pharmaceuticals. According to the world bank records (2018), Egypt is a lower middle income country with gross domestic product of 1.201 trillion dollars, whereas Lebanon is considered an upper middle income country. Therefore, the support from the CBHE is essential as the design and implementation of this diploma/master program will require a huge fund which is unavailable in Egypt and Lebanon, being developed countries.